Objective: We describe a psoriasis patient who let his dog lick his psoriasis lesions, which resulted in nonadherence to prescribed topical calcipotriol/betamethasone dipropiontae (Cal/BD) cutaneous foam. Methods: The patient’s adherence to (Cal/BD) cutaneous foam was objectively monitored by a chip in the medication dispenser and the patient was subsequently visited at his home to observe the dog’s licking process and obtain clinical photos. Conclusion: Topical antipsoriatic drugs containing corticosteroid/calcipotriol preparations are first-line treatment for mild-to-moderate psoriasis, but adherence rates to topical antipsoriatic drugs are low and a barrier for full efficacy of the treatment. Physicians should be aware that a dog licking off psoriasis scales can lead to nonadherence to topical treatment as well as expose the dog owners and their dogs to a risk of adverse events.